PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR + HER2 negative with known BRCA1/2 Mutations
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to test a new cancer treatment drug called PF-01367338 in combination with an FDA approved chemotherapy drug called cisplatin to see what effects (good and bad) it has on cancer.
Description
The purpose of this study is to test a new cancer treatment drug called PF-01367338 in combination with an FDA approved chemotherapy drug called cisplatin to see what effects (good and bad) it has on cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1011003554
